State Street SPDR S&P Biotech ETF
432 hedge funds and large institutions have $5.71B invested in State Street SPDR S&P Biotech ETF in 2018 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 174 increasing their positions, 119 reducing their positions, and 50 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 119
12% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 50
0% more funds holding
Funds holding: 431 → 432 (+1)
1% less capital invested
Capital invested by funds: $5.76B → $5.71B (-$52.8M)
4.69% less ownership
Funds ownership: 111.25% → 106.56% (-4.7%)
9% less funds holding in top 10
Funds holding in top 10: 22 → 20 (-2)
59% less call options, than puts
Call options by funds: $762M | Put options by funds: $1.86B
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$187M |
| 2 |
JP Morgan Chase
New York
|
+$157M |
| 3 |
Rafferty Asset Management
New York
|
+$48.6M |
| 4 |
Goldman Sachs
New York
|
+$44.1M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$40.4M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$224M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$129M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$112M |
| 4 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$43.6M |
| 5 |
AssetMark Inc
Concord,
California
|
-$42M |
XBI Hedge Fund Activity: Q3 2018 in Review
432 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2018, worth a combined $5.71B — down 0.92% from $5.76B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new XBI positions and 50 closed out — a net gain of 6 holders — while 174 added to existing stakes and 119 trimmed.
The largest buyer was Bank of America, adding an estimated $187M. The largest seller was Morgan Stanley, cutting an estimated $224M.
- 432 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2018, up from 431 in Q2 2018.
- Funds reported $5.71B of State Street SPDR S&P Biotech ETF stock for Q3 2018, down 0.92% quarter-over-quarter.
- 56 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2018 and 50 closed out, a net change of +6 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2018 was Bank of America, an estimated $187M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2018 was Morgan Stanley, an estimated $224M sold.
Based on aggregated 13F filings for Q3 2018.